In conclusion, this systematic review and meta-analysis supports a role for highly selective 5-HT4 agonists in the treatment of gastroparesis, given the finding of beneficial effects across multiple patient-important outcomes with a relatively favorable safety profile. This evidence concerns the gene HTR4 and gastroparesis.